Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for early or locally advanced triple‑negative breast cancer
CTR20201563Phase 3Completed
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in breast cancer, sponsored by Suzhou Sundia Biotech Co., Ltd.. Started Aug 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20201563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201563.